Physician profile
Michael L Mulhern
NPI 1588975130
$1,058.23
in general payments reported to CMS, 2019-2025
17 companies · $52.58 in 2025
The $52.58 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $163 · 2021: $123 · 2022: $118 · 2023: $165 · 2024: $328 · 2025: $52.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $546.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $401.64 | 2020-2025 | Clareon, Argos, Rocklatan |
| Oyster Point Pharma, INC. | $88.40 | 2022-2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $79.38 | 2019-2020 | |
| Allergan, INC. | $78.76 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $59.31 | 2021 | |
| Astellas Pharma US INC | $57.65 | 2024-2025 | Izervay |
| Carl Zeiss Meditec USA, INC. | $44.05 | 2022-2024 | Iolmaster 700 |
| Sun Pharmaceutical Industries INC. | $42.59 | 2019-2024 | |
| Optos, INC. | $40.46 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $34.07 | 2024 | Xdemvy |
| Alcon Research LLC | $26.23 | 2019 | |
| Apellis Pharmaceuticals, INC. | $19.99 | 2024 | Syfovre |
| Shire North American Group INC | $19.44 | 2019 | |
| Bausch & Lomb Americas INC. | $19.16 | 2024 | Vyzulta |
| Dompe US, INC. | $17.18 | 2024 | Oxervate |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $16.04 | 2022 | |
| Biotissue Holdings INC. | $13.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mulhern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.